Nutrition 21 holds over 70 issued and pending patents associated with the essential minerals, other nutrients, and nutrient combinations. Our patent portfolio also includes a number of pharmaceutical drug product technologies covering combinations of nutrients and prescription drugs. These combination products provide the therapeutic benefits of the prescription drug along with the added nutritional support desired by consumers. Some combinations have been clinically shown to provide enhanced efficacy and/or safety compared to the prescription drug without the added nutrient. Our plan is to work with partners and utilize abbreviated regulatory and clinical programs available for these types of combinations to more rapidly obtain FDA approval to bring these products to market. Nutrition 21 technologies provide a platform for out-licensing opportunities to pharmaceutical companies desiring a novel line of drug products or to obtain years of extended patent protection on their current drug portfolio. Drug-nutrient combination drugs in development include treatments for diabetes, depression, and HIV.